Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22917929 | 0.86 | KMT2A (0.50) | KMT2AMEN1HPGDMAPTRECQL | |
| SCHEMBL10998213 | 0.86 | MAPT (0.46) | HPGDMAPTRECQLDPP4ALDH1A1 | |
| SCHEMBL10812459 | 0.80 | CUL4A (0.42) | KMT2AMEN1HPGDMAPTRECQL | |
| SCHEMBL4906865 | 0.80 | KMT2A (0.54) | KMT2AMEN1HPGDMAPTRECQL | |
| SCHEMBL12533457 | 0.78 | CDC7 (0.43) | KMT2AMEN1HPGDMAPTNPSR1 | |
| SCHEMBL11578876 | 0.78 | MAPT (0.49) | KMT2AMEN1HPGDMAPTRECQL | |
| SCHEMBL5929779 | 0.77 | KMT2A (0.54) | KMT2AMEN1HPGDMAPTNPSR1 | |
| SCHEMBL31513547 | 0.77 | KMT2A (0.51) | KMT2AMEN1HPGDMAPTRECQL | |
| SCHEMBL19814475 | 0.77 | KMT2A (0.51) | KMT2AMEN1HPGDMAPTRECQL | |
| SCHEMBL25656120 | 0.76 | KMT2A (0.53) | KMT2AMEN1MAPTNPSR1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
| US-4560689-A | ANTICONVULSANTS, ANTIDEPRESSANTS, SEDATIVE ANTIDOTES, AND ANTIEPLILEPTIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1985-12-24 | — | — | US | disclosed |
| US-4479955-A | ANTICONVULSANTS, ANTIDEPRESSANTS, ANTIEPILEPTIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1984-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | KMT2A 2166/4885MEN1 2997/4885HPGD 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.